---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-168614"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:02:21.705274+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics licenses veligrotug, VRDN-003 to Kissei for Japan; $70M upfront, up to $315M milestones

## Summary
- Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.
- Tiered royalties on Japan net sales in the 20s to mid-30s percent range.
- Kissei gets exclusive Japan rights; Viridian retains manufacturing/supply responsibilities except limited cases.
- Veligrotug (VRDN-001) and VRDN-003 are anti-IGF-1R antibodies targeting thyroid eye disease.
- THRIVE and THRIVE-2 phase 3 trials for veligrotug met all primary and secondary endpoints.

## SEC filing metadata
- accession: 0001193125-25-168614
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312525168614/0001193125-25-168614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312525168614/d24708d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-168614
- JSON: https://secwatch.observer/filing/0001193125-25-168614.json
- Plain text: https://secwatch.observer/filing/0001193125-25-168614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.